Christopher G. Bunick, MD, PhD

Selectivity of TYK2 Inhibition in Psoriasis

Panelists discuss the questions below in this video.

How does the selectivity of TYK2 inhibition differ from JAK inhibition?


At what level of pathway inhibition (% inhibition of IL-12, IL-23, IFN) do we see efficacy without safety liabilities, and how narrow or wide is this therapeutic window compared to JAK inhibitors?


Loss-of-function TYK2 variants have been linked to protection from psoriasis. How do these genetic findings inform our understanding of TYK2’s role and support selective inhibition as a therapeutic strategy?

Videos

Next-generation TIC-2 inhibitors show remarkable selectivity, enhancing efficacy while minimizing side effects, offering insights into immune system safety.

Therapeutic Potential of TYK2 Inhibition in Psoriasis

TYK2 is a member of the JAK family but is structurally distinct. Can you elaborate on the mechanistic role of TYK2 in psoriasis pathophysiology?

Explore the distinct role of TIC-2 in psoriasis and how selective inhibition offers targeted treatment advantages over traditional JAK inhibitors.

Challenges with Current Psoriasis Therapies


What are the biggest challenges you face with current psoriasis therapies in terms of durability, access, and adherence? What limitations do providers and patients face with therapies such as biologics or oral small molecules, and what quality of life concerns remain inadequately addressed by current therapies?


Experts discuss the future of psoriasis treatment, highlighting the potential of oral therapies to enhance patient adherence and quality of life.

Role of Mechanisms of Action in Treatment Decisions and Personalized Care in Psoriasis

Panelists discuss the questions below in this video.
As treatment classes have expanded to target distinct immunologic pathways, how do differences in mechanism of action influence your sequencing and personalized treatment decisions?

Explore the complexities of psoriasis treatment, including advanced therapies, mechanisms of action, and the potential of molecular testing for personalized care.

Christopher G. Bunick, MD, PhD

Articles